Rinkus Keith M, Russell Gregory B, Levine Edward A
Department of Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.
Am Surg. 2002 May;68(5):482-7.
The administration of preoperative radiation (Pre-Op) therapy for adenocarcinoma of the rectum is evolving. The prognostic value of nodal disease found after preoperative therapy is unclear. The purpose of this study is to evaluate the impact of Pre-Op therapy on nodal staging and thus prognosis in patients with operable cancer of the rectum. Retrospective review of 292 cases revealed that 20% (N = 58) received Pre-Op radiation and 33% (N = 97) received Post-Op radiation. Of the Pre-Op group 66% received 5-fluorouracil-based chemotherapy concomitantly (vs 48% Post-Op). Radiation dose averaged 50 Gy for both groups. Node-positive disease was found after Pre-Op therapy at a similar rate to that of Post-Op or surgery-only patients (45% vs 46%, P = 0.95). Fewer nodes were found in Pre-Op resection specimens (6.8 vs 10.0 nodes/specimen, P = 0.003), which altered the fraction of positive nodes (27% Pre-Op vs 18% Post-Op, P = 0.003). The N0 cases had better survival than N+ in both Pre-Op (80% vs 34%, P = 0.0001) and Post-Op (70% vs 40%, P = 0.02) groups. There was no significant difference in survival between Pre-Op versus Post-Op. Pre-Op chemoradiation improved patient survival over radiation alone and should be considered routinely with radiation therapy for rectal cancer. Pre-Op radiotherapy decreases the number of nodes recovered but does not influence the presence of nodal metastasis. Nodal disease remains a strong prognostic indicator of survival after Pre-Op radiation therapy.
直肠癌术前放疗的应用正在不断发展。术前治疗后发现的淋巴结疾病的预后价值尚不清楚。本研究的目的是评估术前治疗对可手术直肠癌患者淋巴结分期及预后的影响。对292例病例的回顾性分析显示,20%(N = 58)接受了术前放疗,33%(N = 97)接受了术后放疗。术前放疗组中66%同时接受了基于5-氟尿嘧啶的化疗(术后放疗组为48%)。两组的放疗剂量平均为50 Gy。术前治疗后发现淋巴结阳性疾病的发生率与术后放疗或单纯手术患者相似(45%对46%,P = 0.95)。术前切除标本中发现的淋巴结较少(6.8个/标本对10.0个/标本,P = 0.003),这改变了阳性淋巴结的比例(术前放疗组为27%,术后放疗组为18%,P = 0.003)。在术前放疗组和术后放疗组中,N0病例的生存率均高于N+病例(80%对34%,P = 0.0001;70%对40%,P = 0.02)。术前放疗与术后放疗的生存率无显著差异。术前同步放化疗比单纯放疗提高了患者生存率,应考虑将其作为直肠癌放疗的常规治疗方式。术前放疗减少了回收的淋巴结数量,但不影响淋巴结转移的存在。淋巴结疾病仍然是术前放疗后生存的一个强有力的预后指标。